NEW YORK (GenomeWeb News) – Swiss biochemical extraction company Spinomix has closed a Series A equity investment of $3 million, with the funds coming from existing and new investors, the company said today.

The round of financing was led by Debiopharm Group, a collection of biopharmaceutical companies focused on drug development and investing in startups, primarily in the molecular diagnostics and personalized medicine fields. The funding also included support from previous investors and a private, undisclosed US-based investor group.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.